Dynamics of fecal microbiota in hospitalized elderly fed probiotic LKM512 yogurt

Microbiology and Immunology

Volumn 53, Issue 8, 2009, Pages 421-432

  Matsumoto, Mitsuharu ^a,b   Sakamoto, Mitsuo ^b   Benno, Yoshimi ^c  

^a JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^b RIKEN BIORESOURCE CENTER   (Japan)

^c RIKEN   (Japan)

Author keywords

Intestinal microbiota; Polyamine; Probiotics; Real time PCR; Terminal restriction fragment length polymorphism

Indexed keywords

LACTIC ACID; PLACEBO; PROBIOTIC AGENT; YOGHURT; POLYAMINE;

AGED; ARTICLE; BACTERIAL CELL; BACTERIAL STRAIN; BIFIDOBACTERIUM ANIMALIS; CONTROLLED STUDY; ELDERLY CARE; FECES MICROFLORA; FEMALE; HUMAN; HUMAN EXPERIMENT; INTESTINE FLORA; LACTOBACILLUS DELBRUECKII; MALE; METABOLITE; NUCLEOTIDE SEQUENCE; REAL TIME POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; STREPTOCOCCUS THERMOPHILUS; BACTERIUM; CHEMISTRY; CLINICAL TRIAL; FECES; GENETICS; GROWTH, DEVELOPMENT AND AGING; HOSPITALIZATION; INTESTINE; ISOLATION AND PURIFICATION; METABOLISM; MICROBIOLOGY;

BACTERIA (MICROORGANISMS); BIFIDOBACTERIUM ANIMALIS SUBSP. LACTIS; LACTOBACILLUS; LACTOBACILLUS DELBRUECKII SUBSP. BULGARICUS; STREPTOCOCCUS THERMOPHILUS; UNCULTURED BACTERIUM;

AGED; BACTERIA; BIOGENIC POLYAMINES; FECES; FEMALE; HOSPITALIZATION; HUMANS; INTESTINES; MALE; PROBIOTICS; YOGURT;

EID: 70349303512     PISSN: 03855600     EISSN: 13480421     Source Type: Journal    
DOI: 10.1111/j.1348-0421.2009.00140.x     Document Type: Article

References (41)

1. Finegold S.M., Sutter V.L., Mathisen G.E. (1983) Normal indigenous flora. In:Hentges D., ed. Human intestinal microflora in health and disease. New York: Academic Press, pp. 3-31.
2. Kelly D., Conway S., Aminov R. (2005) Commensal gut bacteria: mechanisms of immune modulation. Trends Immunol. 26: 326-33.
3. Suau A., Bonnet R., Sutren M., Godon J.J., Gibson G.R., Collins M.D., Dore J. (1999) Direct analysis of genes encoding 16S rRNA from complex communities reveals many novel molecular species within the human gut. Appl Environ Microbiol 65: 4799-807.
4. Sakamoto M., Takeuchi Y., Umeda M., Ishikawa I., Benno Y. (2003) Application of terminal RFLP analysis to characterize oral bacterial flora in saliva of healthy subjects and patients with periodontitis. J Med Microbiol 52: 79-89.
5. Matsumoto M., Benno Y. (2007) The relationship between microbiota and polyamine concentration in human intestine: a pilot study. Microbiol Immunol 51: 25-35.
6. Matsumoto M., Sakamoto M., Hayashi H., Benno Y. (2005) Novel phylogenetic assignment database for terminal-restriction fragment length polymorphism analysis of human colonic microbiota. J Microbiol Methods 61: 305-19.
7. Matsumoto M., Kakizoe K., Benno Y. (2007) Comparison of fecal microbiota and polyamine concentration in adult patients with intractable atopic dermatitis and healthy adults. Microbiol Immunol 51: 37-46.
8. Isolauri E., Arvola T., Sutas Y., Moilanen E., Salminen S. (2000) Probiotics in the management of atopic eczema. Clin Exp Allergy 30: 1604-10.
9. Kalliomaki M., Salminen S., Arvilommi H., Kero P., Koskinen P., Isolauri E. (2001) Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial. Lancet 357: 1076-9.
10. Fedorak R.N., Madsen K.L. (2004) Probiotics and the management of inflammatory bowel disease. Inflamm Bowel Dis 10: 286-99.
11. Kirjavainen P.V., Arvola T., Salminen S.J., Isolauri E. (2002) Aberrant composition of gut microbiota of allergic infants: a target of bifidobacterial therapy at weaning? Gut 51: 51-5.
12. Mohan R., Koebnick C., Schildt J., Schmidt S., Mueller M., Possner M., Radke M., Blaut M. (2006) Effects of Bifidobacterium lactis Bb12 supplementation on intestinal microbiota of preterm infants: a double-blind, placebo-controlled, randomized study. J Clin Microbiol 44: 4025-31.
13. Jernberg C., Sullivan A., Edlund C., Jansson J.K. (2005) Monitoring of antibiotic-induced alterations in the human intestinal microflora and detection of probiotic strains by use of terminal restriction fragment length polymorphism. Appl Environ Microbiol 71: 501-6.
14. Pegg A.E., Mccann P.P. (1982) Polyamine metabolism and function. Am J Physiol 243: C212-21.
15. Murphy G.M. (2001) Polyamines in the human gut. Eur J Gastroenterol Hepatol 13: 1011-14.
16. Zhang M., Caragine T., Wang H., Cohen P.S., Botchkina G., Soda K., Bianchi M., Ulrich P., Cerami A., Sherry B., Tracey K. (1997) Spermine inhibits proinflammatory cytokine synthesis in human mononuclear cells: A counterregulatory mechanism that restrains the immune response. J Exp Med 185: 1759-68.
17. Matsumoto M., Kimata H., Benno Y., Kamio S. (2008) Impact of spermine on down-regulation of Th2 cytokines in peripheral blood mononuclear cells from cedar pollinosis subjects in vitro. Biosci Biotechnol Biochem 72: 1604-6.
18. Bardocz S., Grant G., Brown D.S., Pusztai A. (1998) Putrescine as source of instant energy in the small intestine of the rat. Gut 42: 24-8.
19. Milovic V. (2001) Polyamines in the gut lumen: bioavailability and biodistribution. Eur J Gastroenterol Hepatol 13: 1021-5.
20. Noack J., Kleesen B., Proll J., Dongowski G., Blaut M. (1998) Dietary guar gum and pectin stimulate intestinal microbial polyamine synthesis in rats. J Nutr 128: 1385-91.
21. +-ATPase activity in Bifidobacterium with special reference to acid tolerance. Int J Food Microbiol 93: 109-13.
22. Matsumoto M., Tani H., Ono H., Ohishi H., Benno Y. (2002) Adhesive property of Bifidobacterium lactis LKM512 and predominant bacteria of intestinal microflora to human intestinal mucin. Curr Microbiol 44: 212-5.
23. Matsumoto M., Ohishi H., Benno Y. (2001) Impact of LKM512 yogurt on improvement of intestinal environment of the elderly. FEMS Immunol Med Microbiol 31: 181-6.
24. Matsumoto M., Benno Y. (2006) Consumption of probiotic yogurt containing Bifidobacterium animalis subsp. lactis LKM512 produces anti-inflammatory metabolites in the gut. Biosci Biotech Biochem 70: 1287-92.
25. Matsumoto M., Benno Y. (2004) Consumption of Bifidobacterium lactis LKM512 yogurt reduces gut mutagenicity by increasing gut polyamine contents in healthy adult subjects. Mutat Res Fund Mol Mechan Mutagenesis 568: 147-53.
26. Matsuki T., Watanabe K., Fujimoto J., Kado Y., Takada T., Matsumoto K., Tanaka R. (2004) Quantitative PCR with 16S rRNA-gene-targeted species-specific primers for analysis of human intestinal bifidobacteria. Appl Environ Microbiol 70: 167-73.
27. Lane D.J. 1991. 16S/23S rRNA sequence, p. 115-175. In:Stackebrandt E., Goodfellow M., eds. Nucleic Acid Techniques in Bacterial Systematics. New York: John Wiley and Sons.
28. Hayashi H., Sakamoto M., Benno Y. (2004) Evaluation of three different forward primers by terminal restriction fragment length polymorphism analysis for detemination of fecal Bifidobacterium spp. in healthy subjects. Microbiol Immunol 48: 1-6.
29. Sakamoto M., Hayashi H., Benno Y. (2003) Terminal restriction fragment length polymorphism analysis for human fecal microbiota and its application for analysis of complex bifidobacterial communities. Microbiol Immunol 47: 133-42.
30. Malinen E., Kassinen A., Rinttila T., Palva A. (2003) Comparison of real-time PCR with SYBR Green I or 5′-nuclease assays and dot-blot hybridization with rDNA-targeted oligonucleotide probes in quantification of selected faecal bacteria. Microbiology 149: 269-77.
31. Nadkarni M.A., Martin F.E., Jacques N.A., Hunter N. (2002) Determination of bacterial load by real-time PCR using a broad-range (universal) probe and primers set. Microbiology 148: 257-66.
32. Rinttila T., Kassinen A., Malinen E., Krogius L., Palva A. (2004) Development of an extensive set of 16S rDNA-targeted primers for quantification of pathogenic and indigenous bacteria in faecal samples by real-time PCR. J Appl Microbiol 97: 1166-77.
33. Bartosch S., Woodmansey E.J., Paterson J.C., Mcmurdo M.E., Macfarlane G.T. (2005) Microbiological effects of consuming a synbiotic containing Bifidobacterium bifidum, Bifidobacterium lactis, and oligofructose in elderly persons, determined by real-time polymerase chain reaction and counting of viable bacteria. Clin Infect Dis 40: 28-37.
34. Benno Y., Mitsuoka T. (1992) Impact of Bifidobacterium longum on human fecal microflora. Microbiol Immunol 36: 683-94.
35. Matsumoto M., Tadenuma T., Nakamura K., Kume H., Imai T., Kihara R., Watanabe M., Benno Y. (2000) Effect of Bifidobacterium lactis LKM 512 yoghurt on fecal microflora in middle to old aged persons. Microbial Ecol Health Dis 12: 77-80.
36. Scardovi V., Crociani F. (1974) Bifidobacterium catenulatum, Bifidobacterium dentium, and Bifidobacterium angulatum: three new species and their deoxyribonucleic acid homology relationships. Int J Syst Bacteriol 24: 6-20.
37. Scardovi V., Trovatelli L.D., Biavati B., Zani G. (1979) Bifidobacterium cuniculi, Bifidobacterium choerinum, Bifidobacterium boum, and Bifidobacterium pseudocatenulatum: four new species and their deoxyribonucleic acid homology relationships. Int J Syst Bacteriol 29: 291-311.
38. Ogata T., Kingaku M., Yaeshima T., Teraguchi S., Fukuwatari Y., Ishibashi N., Hayasawa H., Fujisawa T., Iino H. (1999) Effect of Bifidobacterium longum BB536 yogurt administration on the intestinal environment of healthy adults.Microbial Ecol Health Dis 11: 41-6.
39. Ahmed M., Prasad J., Gill H., Stevenson L., Gopal P. (2007) Impact of consumption of different levels of Bifidobacterium lactis HN019 on the intestinal microflora of elderly human subjects. J Nutr Health Aging 11: 26-31.
40. Medina M.A., J.L., U., Rodriguez-Caso C., Ramirez J., Sanchez-Jimenez F. (2003) Biogenic amines and polyamines: similar biochemistry for different physiological missions and biomedical applications. Crit Rev Biochem Mol Biol 38: 23-59.
41. Matsumoto, M., Aranami, A., Ishige, A., Watanabe, K. and Benno, Y. (2007) LKM512 yogurt consumption improves the intestinal environment and induces the Th1-type cytokine in adult patients with intractable atopic dermatitis. Clin Exp Allergy 37: 358-370.